# Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

> **NCT00300274** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 721 (actual)

## Conditions studied

- Graft Rejection

## Interventions

- **DRUG:** everolimus
- **DRUG:** mycophenolate mofetil
- **DRUG:** cyclosporine
- **DRUG:** corticosteroids

## Key facts

- **NCT ID:** NCT00300274
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 721 (ACTUAL)
- **Last updated:** 2012-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300274, "Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00300274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*